Form 4: ADMA Director Steve Elms Boosts Stake

ADMA Biologics Director Steve Elms reported acquiring 10,690 restricted stock units and 17,730 stock options, increasing his direct and indirect beneficial ownership.

Summary

• Director Steve Elms acquired 10,690 Restricted Stock Units (RSUs) of ADMA Biologics, Inc. common stock on February 9, 2026, with a grant price of $0.
• These RSUs will vest in two equal installments on the sixand 12-month anniversaries of the grant date, becoming fully vested on February 9, 2027, subject to continued service.
• Mr. Elms also acquired 17,730 stock options with an exercise price of $16.37 on February 9, 2026, which will vest in twelve equal monthly installments, becoming fully vested on February 9, 2027.
• Following these transactions, Mr. Elms directly beneficially owns 98,020 shares of common stock, which includes the newly granted 10,690 RSUs, 5,445 previously granted RSUs (vesting February 19, 2026), and 81,885 shares of common stock.
• Mr. Elms indirectly beneficially owns 2,031,730 shares of common stock through Aisling Capital II LP, where he is a Managing Member of Aisling Capital Partners, LLC and a member of the investment committee of Aisling Capital Partners, LP. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. Insider acquisitions, especially by a director and significant owner, typically indicate confidence in the company's future and potential for growth.

Positives

• Director Steve Elms' acquisition of 10,690 Restricted Stock Units and 17,730 stock options signals increased insider confidence in ADMA Biologics' future performance.
• The vesting schedules for both RSUs and stock options align Mr. Elms' long-term interests with those of shareholders, promoting sustained engagement and performance.

Future Outlook

The acquired Restricted Stock Units and stock options are subject to vesting schedules, with full vesting expected on February 9, 2027, contingent on Mr. Elms' continued service to the company. This indicates a forward-looking commitment from the director.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a director and 10% owner, is often interpreted by the market as a positive signal, suggesting that those closest to the company believe its shares are undervalued or expect future positive developments. This action aligns the director's financial interests more closely with the company's long-term success, a common practice in the biotechnology and pharmaceutical sectors to incentivize leadership.

Related Party Transactions

• Steve Elms' indirect beneficial ownership of 2,031,730 shares is through Aisling Capital II LP. Mr. Elms is a Managing Member of Aisling Capital Partners, LLC (a control person of Aisling) and a member of the investment committee of Aisling Capital Partners, LP (Aisling GP). He disclaims beneficial ownership of Aisling's investment in the Issuer except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: The acquisition of additional equity by a director and 10% owner can be seen as a positive indicator, potentially boosting investor confidence and aligning management interests with shareholder value creation.
• Employees: Continued service requirements for vesting of RSUs and options may reinforce stability and long-term commitment from key personnel.

Next Steps

• The 10,690 RSUs will vest in two equal installments on the sixand 12-month anniversaries of the grant date (February 9, 2026), becoming fully vested on February 9, 2027.
• The 17,730 stock options will vest in twelve equal monthly installments, becoming fully vested on February 9, 2027.
• The 5,445 unvested RSUs from the February 19, 2025 grant will vest fully on February 19, 2026.

Key Dates

Recommendation

The acquisition of additional equity by a director and 10% owner, Steve Elms, is a strong insider signal. Such actions typically indicate that those with deep knowledge of the company's operations and prospects believe the stock is undervalued or anticipate positive future developments. This insider buying suggests confidence in ADMA Biologics' long-term value proposition, making it a 'buy' signal for investors.

Keywords

ADMA Biologics, ADMA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Beneficial Ownership, Director, Equity Compensation